Replies to post #86208 on NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Excellent post, particularly the early verse late.

[Cancerfix]

Hmmm....i Think when placebo patients is registret with tumor growth, it count as one event? Am i wrong on this?

[Pablosrv]

Yes, thanks a lot iwasadiver, it really helps a lot.
So, all in all, it would be really positive for the trial. The only disadvantage would be that it is more complicated for the company to "calculate" results....but as long as we remain patient, we shoudlnt care much, right? The "everybody is living longer" should be really something awesome for us longs here.

[Docinvestor]

The blind prevent you from knowing in which group patients are, even Linda Liau can't see crossovers so when she stated that all patients are living longer it may very well mean only those that are in treatment group.

The most important will be primary endpoint, if it is met then conditional approval is guaranteed in Europe whatever are the OS figures as long as there is a numerical advantage for treatment.

Best wishes,

Docinvestor

[Astavakra]

Clearly put, iwasadiver. Thanks. I agree totally. I'm making a note of this post so that I can repost it every time this comes up.

[pgsd]

Best explanation to date.

[md1225]

"Chris patients in our open arm of our trial which might I add NO other company does, are living over three years on average do you realize what that alone means to this population of patients?"

From conversation a couple days ago.....

[Smokey21]

It is also not "helping our study" because it will take longer to get to the point of secondary endpoint events threshold to calculate the MOS.